Heat shock protein inhibitors in the management of CRPC and mCRPC: an update

An investigational agent known as ganetespib failed to show significant clinical activity as monotherapy in a heavily pretreated cohort of men with metastatic, castration-resistant prostate cancer (mCRPC) who had received prior, docetaxel-based chemotherapy. … READ MORE …

Does normal expression of SPOP prevent development of many prostate cancers?

Researchers from the Mayo Clinic in Rochester, MN, are claiming that they have made a series of four important discoveries related to the role of a protein called “speckle-type POZ protein” (SPOP) and its involvement in the development of prostate cancer. … READ MORE …

Perhaps all too much FUS about something …

As usual, some of our friends in the media are over-hyping a recent publication about the possible effects of a protein called FUS/TLS in the progression of prostate cancer. … READ MORE …